1-[(4-氯苯基)磺酰基]-4-(2-甲氧基苯基)哌嗪 | 5279-23-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-[(4-氯苯基)磺酰基]-4-(2-甲氧基苯基)哌嗪
• 英文名称: 1-(4-chloro-benzenesulfonyl)-4-(2-methoxy-phenyl)-piperazine
• 英文别名: 1-((4-Chlorophenyl)sulfonyl)-4-(2-methoxyphenyl)piperazine；1-(4-chlorophenyl)sulfonyl-4-(2-methoxyphenyl)piperazine
• CAS: 5279-23-2
• 化学式: C₁₇H₁₉ClN₂O₃S
• mdl: MFCD00592925
• 分子量: 366.868
• InChiKey: WTXZSPLQEKAFCB-UHFFFAOYSA-N

物化性质

• 溶解度：
  4 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  58.2
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 海关编码：
  2933599090

文献信息

• N-cyclic sulfonamido inhibitors of gamma secretase
  申请人：Neitzel L. Martin

  公开号：US20060035884A1

  公开（公告）日：2006-02-16

  The invention provides N-cyclic sulfonamido compounds for use in treating or preventing cognitive disorders, such as Alzheimer's Disease. Compounds of particular interest are defined by Formula I, wherein R 4 , R 5 , R 6 , R 7 , and R 8 , are as described in the specification. The invention also encompasses pharmaceutical compositions comprising compounds of Formula I as well as methods of treating cognitive disorders, including Alzheimer's disease using compounds of Formula I.

  本发明提供了用于治疗或预防认知障碍（如阿尔茨海默病）的 N-环磺酰胺基化合物。 特别感兴趣的化合物由式 I 定义，其中 R 4 , R 5 , R 6 , R 7 和 R 8 如说明书所述。本发明还包括由式 I 化合物组成的药物组合物，以及使用式 I 化合物治疗认知障碍（包括阿尔茨海默病）的方法。
• N-CYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE
  申请人：ELAN PHARMACEUTICALS, INC.

  公开号：EP1758884A2

  公开（公告）日：2007-03-07
• [EN] N-CYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE<br/>[FR] INHIBITEURS SULFONAMIDO N-CYCLIQUES DE GAMMA-SECRETASE
  申请人：ELAN PHARM INC

  公开号：WO2005113542A2

  公开（公告）日：2005-12-01

  The invention provides N-cyclic sulfonamido compounds for use in treating or preventing cognitive disorders, such as Alzheimer’s Disease. Compounds of particular interest are defined by Formula (I), wherein R4, R5, R6, R7 and R8 are as described in the specification. The invention also encompasses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of treating cognitive disorders, including Alzheimer’s disease using compounds of Formula (I).